This subgroup analysis of the randomized, open-label, parallel-group EXCITE-HT study explored the antihypertensive efficacy and safety of esaxerenone vs trichlormethiazide in patients with type 2 diabetes mellitus (T2DM), stratified by baseline antihypertensive agent (angiotensin receptor blocker [ARB] or calcium channel blocker [CCB]) and urinary albumin-to-creatinine ratio (UACR; <30 or ≥30 mg/gCr). Here, ALB is linked to type 2 diabetes mellitus.